Navigation Links
Regional Biotech Association Urges Support for Biosimilars Bill in Congress

BOSTON, Sept. 22 /PRNewswire/ -- A vast coalition of New England business leaders today joined the New England Biotech Association (NEBA) to push for Congress to approve a legislative pathway for biosimilars that protect patient safety but also provide sufficient incentives for new innovative products to be developed.

NEBA and 27 other organizations and biotechnology leaders across New England said in a letter to all members of the New England congressional delegation that the biosimilars legislation is the single biggest issue in protecting the future viability and growth of New England's biotechnology industry: "New biologic medicines represent the greatest hope for treating diseases such as cancer, asthma, Parkinson's, and Alzheimers. It is crucial that biosimilars legislation preserve the incentives necessary for biotech researchers to develop the next breakthrough medical treatments. These incentives should include an appropriate period of 12-years of data exclusivity to allow New England's biotech companies to attract and protect the massive investment necessary to develop a biologic."

During its recent consideration of health care reform legislation, both the Senate Health, Education, Labor and Pensions (HELP) Committee and the House Energy and Commerce Committee adopted bipartisan amendments that provide a safe, effective and reasonable pathway for the approval of biosimilars. These amendments, approved by overwhelmingly bipartisan votes, strike the right balance between expanding competition to lower costs for consumers and preserving incentives for continued biomedical innovation by providing a 12-year period of data exclusivity.

If the final legislation approved by Congress does not protect patient safety and provide sufficient incentives for investment in innovative new biologic medicines, it would deliver a devastating blow to the hope held by millions of patients and seriously undermine the region's biotech sector."

As the regional policy and public affairs voice for the biotechnology and biopharmaceutical community, NEBA represents state biotech associations, companies, academic institutions, and other organizations from all six New England states.

To find out more about NEBA, visit

SOURCE New England Biotech Association
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
2. A Magnetic Gift: Sumter Regional Hospital Receives New MRI as Charitable Donation From Siemens
3. onTargetjobs Announces Acquisition of
4. Strengthens Local Market Candidate Reach Through Acquisition
5. Strengthens Local Market Candidate Reach Through Acquisition
6. Strengthens Local Market Candidate Reach Through Acquisition
7. China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products
8. New Regional Biotech Association Formed
9. Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission
10. Regional Biotech Association Warns Vermont Legislation Could Have Profound Negative Impact
11. Midwest Research Institute Expands in Kansas to Support Regional Economic Development in Animal Health, Biosecurity, and Bioenergy Sectors
Post Your Comments:
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... event of the year and one of the premier annual events for pharmaceutical ... ran from 8–11 November 2015, where ISPE hosted the largest number of attendees ...
(Date:11/24/2015)... 24, 2015 --> ... report "Oligonucleotide Synthesis Market by Product & Services (Primer, ... Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic ... the market is expected to reach USD 1,918.6 Million ... a CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... market report published by Transparency Market Research "Home Security Solutions ... and Forecast 2015 - 2022", the global home security solutions ... bn by 2022. The market is estimated to expand ... from 2015 to 2022. Rising security needs among customers ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
(Date:10/27/2015)... October 27, 2015 Munich, ... Gaze Mapping technology (ASGM) automatically maps data from mobile ... Glasses , so that they can be quantitatively ... Munich, Germany , October 28-29, 2015. ... data from mobile eye tracking videos created with ...
Breaking Biology News(10 mins):